Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Product › Details

NHance™ technology

Products Next higher product group Fc engineering technology
Period Status 2012-03-19 sales start
Organisation Organisation Argen-X B.V.
  Today Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
  Group Argenx (Argen-X) (Group)
  Original research University of Texas, Southwestern Medical Center (UT Southwestern, Dallas)
     

Argen-X B.V.. (3/19/12). "Press Release: Argen-X Launches NHance Technology to Generate Better Human Antibody Therapies. Adds a Second Proprietary Platform to Leverage the Power of the SIMPLE Antibody Platform". Rotterdam & Ghent.

arGEN-X announces today the launch of NHance™, its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics.

NHance™ technology significantly prolongs the circulation time of therapeutic antibodies in the human body by engineering of the antibody constant region (Fc). The technology provides a new treatment paradigm in terms of reduced antibody dosing, increased efficacy and improved overall convenience to the patient.

NHance™ is superior to existing Fc engineering approaches delivering superior pharmacokinetics without impairing the antibody's Fc-mediated cell-killing effects. The technology has been thoroughly validated, including through PK studies in appropriate pre-clinical models.

NHance™ is based on proprietary Fc region mutations and was invented by Dr. Sally Ward, Professor of Immunology at the University of Texas Southwestern Medical Center, a world renowned pioneer in this field of antibody biology. arGEN-X has acquired an exclusive global license to the technology.

arGEN-X will apply the NHance™ technology both to its partners' antibody discovery programs and to its own therapeutic antibody pipeline. In addition, arGEN-X intends to make the technology available to antibody-focused companies through non-exclusive licenses.

"Our validated SIMPLE Antibody™ platform, which delivers variable regions unrivalled in their functional diversity and therapeutic utility, is key to arGEN-X's success," says Prof. Dr. Hans de Haard, Chief Scientific Officer. "We had previously complemented the SIMPLE platform with state-of-the-art ADCC-enhancement through our Potelligent® license agreement with BioWa. We are now further strengthening our cutting-edge capabilities with NHance™ to ensure the optimal differentiation of our antibody products. This suite of technologies underpins our evolution into a real therapeutic antibody powerhouse."

Dr. Torsten Dreier, Chief Development Officer of arGEN-X, comments further: "I am thrilled by the therapeutic potential of NHance™, which delivers increased efficacy in settings where sustained antibody dosing is critically important. NHance™ is a great solution for improving the dosing convenience for chronically ill patients as well as maximizing the cost-effectiveness of therapeutic antibody treatments."

   
Record changed: 2020-10-08

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for NHance™ technology


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81




» top